Lumida
/ALLO
⌘K
Allogene Therapeutics Inc

Allogene Therapeutics Inc

ALLO
$1.98USD+0.00%+0.00 today

MARKET CAP

684.1M

P/E (TTM)

FWD P/E

DAY RANGE

$2 – $2

52W RANGE

$1
$4

AI Summary

Stalk
TrimMedium

Following a Stage 1 consolidation attempt after a terminal decline, the stock exhibits a repaired EMA regime yet remains under an active Lower Highs & Lower Lows pattern, reinforcing a medium-term bearish bias. In the short term, price is tightly tracking above the rising 9/21-EMA zone without a clear rejection signal, arguing for patience and deferred execution until a more decisive breakdown or EMA rejection occurs.

  • Phase 2 ALPHA3 trial cema-cel shows 58.3% MRD negativity vs 16.7% control.
  • FDA granted RMAT and Fast Track designations, expediting approval path.
  • Negative earnings yield and profitability scores signal weak returns.
Full analysis →
Insider Trades31 trades
DateSideTickerInsiderRoleSharesPriceMkt Cap52W High52W LowValue% ChgRuleAI View
Apr 21, 2026SellALLOAnnie YoshiyamaSVP, Finance9,586$2.31$684.1M-55.61%+90.38%$22.1K-7.15%Trim
Mar 31, 2026SellALLOBenjamin Machinas BeneskiSVP, Chief Technical Officer2,867$2.50$684.1M-55.61%+90.38%$7.2K-1.45%Trim
Mar 16, 2026SellALLOBenjamin Machinas BeneskiSVP, Chief Technical Officer4,835$2.47$684.1M-55.61%+90.38%$11.9K-2.38%Trim
Mar 16, 2026SellALLODavid D ChangPresident and CEO47,763$2.47$684.1M-55.61%+90.38%$118.0K-0.92%Trim
Mar 2, 2026SellALLOBenjamin Machinas BeneskiSVP, Chief Technical Officer7,132$2.60$684.1M-55.61%+90.38%$18.5K-3.39%Trim
Feb 2, 2026SellALLOAnnie YoshiyamaSVP, Finance4,167$1.72$684.1M-55.61%+90.38%$7.2K-1.14%Trim
Feb 2, 2026SellALLOBenjamin Machinas BeneskiSVP, Chief Technical Officer7,549$1.73$684.1M-55.61%+90.38%$13.1K-1.08%Trim
Feb 2, 2026SellALLOEarl Martin DouglasSVP, General Counsel22,900$1.76$684.1M-55.61%+90.38%$40.3K-1.79%Trim
Feb 2, 2026SellALLOGeoffrey M. ParkerCHIEF FINANCIAL OFFICER24,001$1.76$684.1M-55.61%+90.38%$42.2K-1.22%Trim
Feb 2, 2026SellALLOZachary RobertsEVP of R&D35,700$1.77$684.1M-55.61%+90.38%$63.2K-2.32%Trim
Feb 2, 2026SellALLODavid D ChangPresident and CEO95,269$1.80$684.1M-55.61%+90.38%$171.5K-1.35%Trim
Jan 21, 2026SellALLOZachary RobertsEVP of R&D26,269$1.56$684.1M-55.61%+90.38%$41.0K-4.08%Trim
Nov 17, 2025SellALLOBenjamin Machinas BeneskiSVP, Chief Technical Officer786$1.22$684.1M-55.61%+90.38%$958.92-0.36%Trim
Oct 21, 2025SellALLOGeoffrey M. ParkerCHIEF FINANCIAL OFFICER36,744$1.26$684.1M-55.61%+90.38%$46.2K-2.80%Trim
Apr 21, 2025SellALLOAnnie YoshiyamaSVP, Finance9,601$1.41$684.1M-55.61%+90.38%$13.5K-6.84%Trim
Mar 14, 2025SellALLOBenjamin Machinas BeneskiSVP, Chief Technical Officer5,488$1.98$684.1M-55.61%+90.38%$10.8K-2.45%Trim
Mar 14, 2025SellALLODavid D ChangPresident and CEO46,668$1.96$684.1M-55.61%+90.38%$91.5K-0.88%Trim
Feb 3, 2025SellALLOGeoffrey M. ParkerCHIEF FINANCIAL OFFICER4,361$1.73$684.1M-55.61%+90.38%$7.5K-0.33%Trim
Feb 3, 2025SellALLOEarl Martin DouglasSVP, General Counsel6,404$1.71$684.1M-55.61%+90.38%$11.0K-1.08%Trim
Feb 3, 2025SellALLOTimothy L. MooreChief Technical Officer14,746$1.71$684.1M-55.61%+90.38%$25.2K-5.55%Trim
Feb 3, 2025SellALLOZachary RobertsEVP of R&D18,832$1.70$684.1M-55.61%+90.38%$32.0K-2.84%Trim
Feb 3, 2025SellALLODavid D ChangPresident and CEO46,003$1.68$684.1M-55.61%+90.38%$77.3K-0.86%Trim
Jan 21, 2025SellALLOZachary RobertsEVP of R&D27,199$1.78$684.1M-55.61%+90.38%$48.4K-5.28%Trim
Oct 21, 2024SellALLOGeoffrey M. ParkerCHIEF FINANCIAL OFFICER36,404$2.84$684.1M-55.61%+90.38%$103.4K-3.12%Trim
Aug 21, 2024SellALLOEarl Martin DouglasSVP, General Counsel28,310$2.79$684.1M-55.61%+90.38%$78.8K-5.93%Trim
May 16, 2024BuyALLODavid D ChangPresident and CEO344,828$2.90$684.1M-55.61%+90.38%$1.0M+7.72%Trim
May 16, 2024BuyALLOGeoffrey M. ParkerCHIEF FINANCIAL OFFICER344,828$2.90$684.1M-55.61%+90.38%$1.0M+42.07%Trim
Apr 22, 2024SellALLOTimothy L. MooreChief Technical Officer17,360$3.47$684.1M-55.61%+90.38%$60.2K-6.14%Trim
Mar 14, 2024SellALLODavid D ChangPresident and CEO53,393$4.33$684.1M-55.61%+90.38%$231.2K-1.18%Trim
Jan 30, 2024BuyALLOGeoffrey M. ParkerCHIEF FINANCIAL OFFICER190$3.60$684.1M-55.61%+90.38%$683.05+0.02%Trim
Jan 22, 2024SellALLOZachary RobertsEVP of R&D24,690$3.17$684.1M-55.61%+90.38%$78.4K-6.17%Trim